정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1633 | Completed | Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment | Coronavirus Infection | Drug: Chloroquine or Hydroxychloroquine | Phase 3 | Tanta University | OTHER | 194 | All | Tanta University, Assiut University, Tanta, Egypt | |
| 1632 | Recruiting | Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 | Adult Respiratory Distress Syndrome | Drug: XCEL-UMC-BETA Other: Placebo |
Phase 2 | Banc de Sang i Teixits | OTHER | 30 | All | 18 Years ~ 75 Years | Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain Mutua de Terrassa, Terrassa, Barcelona, Spain Hospital del Mar, Barcelona, Spain Hospital Vall d'Hebron, Barcelona, Spain Hospital Clinic de Barcelona, Barcelona, Spain |
| 1631 | Recruiting | Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal | COVID-19 | Drug: Nafamostat Mesilate | Phase 3 | Institut Pasteur de Dakar, Fann Hospital, Senegal, Ministry of Health, Senegal, Diamniadio Children Hospital, Senegal, Dalal Jamm Hospital, Senegal, Institut Pasteur Korea | OTHER | 186 | All | 18 Years | Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal Diamniadio Children Hospital, Diamniadio, Senegal Dalal Jamm Hospital, Guediawaye, Senegal |
| 1630 | Recruiting | Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE) | Acute Respiratory Distress Syndrome | Drug: Dornase Alfa Inhalation Solution [Pulmozyme] Procedure: standard procedure |
Phase 3 | Fondation Ophtalmologique Adolphe de Rothschild, University Hospital, Strasbourg, France, Centre Hospitalier Regional Metz-Thionville | NETWORK | 100 | All | 18 Years | Hopital Fondation A. de Rotschhild, Paris, France |
| 1629 | Recruiting | Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019 | COVID-19 | Drug: Anluohuaxian | Not Applicable | Peking University First Hospital | OTHER | 750 | All | 18 Years ~ 80 Years | The Second People's Hospital of Fuyang, Fuyang, Anhui, China Ezhou Central Hospital, Wuhan, Hubei, China Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China Jinyintan Hospital of Wuhan, Wuhan, Hubei, China Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China Wuhan Pulmonary Hospital, Wuhan, Hubei, China Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China |
| 1628 | Not yet recruiting | Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 | COVID-19 | Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir Drug: Standard of care treatment |
Phase 3 | Cairo University | OTHER | 100 | All | 18 Years ~ 65 Years | |
| 1627 | Not yet recruiting | Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care | COVID-19 | Drug: Apixaban | Phase 4 | Scotmann Pharmaceuticals, Rawalpindi Medical College | INDUSTRY | 30 | All | 18 Years |